Total Payments
$815.18
2024 Payments
$163.07
Companies
13
Transactions
23
Medicare Patients
4,634
Medicare Billing
$549,873
Payment Breakdown by Category
Food & Beverage$739.40 (90.7%)
Education$75.78 (9.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $739.40 | 16 | 90.7% |
| Education | $75.78 | 7 | 9.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $155.02 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $133.22 | 3 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $122.81 | 1 | $0 (2019) |
| Kite Pharma, Inc. | $104.53 | 1 | $0 (2018) |
| GENZYME CORPORATION | $77.38 | 2 | $0 (2023) |
| Seattle Genetics, Inc. | $49.16 | 4 | $0 (2019) |
| Daiichi Sankyo Inc. | $47.77 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $30.30 | 1 | $0 (2024) |
| Celgene Corporation | $27.07 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $20.39 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $163.07 | 7 | Daiichi Sankyo Inc. ($47.77) |
| 2023 | $97.65 | 3 | GENZYME CORPORATION ($77.38) |
| 2022 | $20.52 | 1 | E.R. Squibb & Sons, L.L.C. ($20.52) |
| 2019 | $160.66 | 4 | Pharmacyclics LLC, An AbbVie Company ($122.81) |
| 2018 | $260.21 | 6 | PFIZER INC. ($131.10) |
| 2017 | $113.07 | 2 | E.R. Squibb & Sons, L.L.C. ($99.43) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $27.07 | General |
| Category: Hematology | ||||||
| 05/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $30.30 | General |
| Category: Oncology | ||||||
| 10/18/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $38.09 | General |
| Category: Oncology | ||||||
| 06/01/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.27 | General |
| Category: Hematology/Oncology | ||||||
| 05/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $39.29 | General |
| Category: Oncology | ||||||
| 10/10/2022 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Education | In-kind items and services | $20.52 | General |
| Category: Hematology | ||||||
| 05/17/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.27 | General |
| Category: Oncology | ||||||
| 04/24/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $122.81 | General |
| Category: Oncology | ||||||
| 02/21/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 02/07/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 11/14/2018 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/09/2018 | PFIZER INC. | SUTENT (Drug) | Education | In-kind items and services | $3.05 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 07/31/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 06/12/2018 | PFIZER INC. | SUTENT (Drug) | Education | In-kind items and services | $3.05 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 06/05/2018 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $104.53 | General |
| Category: ONC | ||||||
| 04/03/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 11/07/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $99.43 | General |
| Category: Oncology | ||||||
| 06/14/2017 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 552 | 1,162 | $254,757 | $103,288 |
| 2022 | 7 | 514 | 1,107 | $246,165 | $108,596 |
| 2021 | 8 | 570 | 1,345 | $271,773 | $139,660 |
| 2020 | 24 | 2,998 | 7,564 | $445,639 | $198,328 |
Total Patients
4,634
Total Services
11,178
Medicare Billing
$549,873
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 250 | 587 | $155,496 | $65,060 | 41.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 173 | 347 | $66,914 | $25,216 | 37.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 43 | $7,654 | $4,055 | 53.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 76 | 147 | $9,594 | $3,603 | 37.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $9,384 | $3,292 | 35.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 15 | $5,715 | $2,062 | 36.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 201 | 474 | $125,136 | $54,314 | 43.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 196 | 395 | $75,050 | $28,830 | 38.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 20 | 76 | $12,160 | $12,122 | 99.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 70 | $12,658 | $5,617 | 44.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $12,648 | $4,479 | 35.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 15 | $5,385 | $2,057 | 38.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 36 | 46 | $3,128 | $1,178 | 37.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 181 | 380 | $95,318 | $43,919 | 46.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 225 | 553 | $100,769 | $41,038 | 40.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 40 | 242 | $38,720 | $39,252 | 101.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 33 | 36 | $12,809 | $5,663 | 44.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 65 | $11,570 | $5,344 | 46.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $8,283 | $3,105 | 37.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 19 | 28 | $1,904 | $733.60 | 38.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 20 | $2,400 | $604.56 | 25.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 282 | 650 | $112,450 | $48,208 | 42.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 39 | 160 | $25,600 | $25,235 | 98.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 107 | 219 | $51,027 | $22,535 | 44.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 176 | 227 | $39,271 | $14,618 | 37.2% |
About Dr. Mashour Yousef, M.D
Dr. Mashour Yousef, M.D is a Hematology & Oncology healthcare provider based in Newport News, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609893130.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mashour Yousef, M.D has received a total of $815.18 in payments from pharmaceutical and medical device companies, with $163.07 received in 2024. These payments were reported across 23 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($739.40).
As a Medicare-enrolled provider, Yousef has provided services to 4,634 Medicare beneficiaries, totaling 11,178 services with total Medicare billing of $549,873. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Newport News, VA
- Active Since 07/17/2006
- Last Updated 10/01/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1609893130
Products in Payments
- ELIQUIS (Drug) $125.00
- Imbruvica (Drug) $122.81
- OPDIVO (Biological) $112.70
- Yescarta (Drug) $104.53
- SARCLISA (Biological) $77.38
- ADCETRIS (Biological) $49.16
- Enhertu (Drug) $47.77
- KISQALI (Drug) $30.30
- REBLOZYL (Biological) $27.07
- XTANDI (Drug) $23.92
- Pomalyst (Drug) $20.52
- LYNPARZA (Biological) $20.39
- JAKAFI (Drug) $20.27
- BENDEKA (Drug) $13.64
- BRAFTOVI (Drug) $13.62
- SUTENT (Drug) $6.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Newport News
David Chang, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $84,986
Hematology & Oncology $84,986
Bruce Booth, Md, MD
Hematology & Oncology — Payments: $21,024
Hematology & Oncology $21,024
Frankie Powell, Md, MD
Hematology & Oncology — Payments: $4,566
Hematology & Oncology $4,566
Dr. Ligeng Tian, B.m, B.M
Hematology & Oncology — Payments: $4,095
Hematology & Oncology $4,095
Flavia Kostov, M.d, M.D
Hematology & Oncology — Payments: $470.43
Hematology & Oncology $470.43
Vihitha Thota, Md, MD
Hematology & Oncology — Payments: $236.43
Hematology & Oncology $236.43